Latest News and Press Releases

Proof-of-Concept Established in Phase 2 Trial of TGCT, with Positive Efficacy Results Across Multiple Clinical Endpoints and Favorable Safety Profile After 12 Weeks of Therapy with AMB-05X  ​Novel,...

REDWOOD CITY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including the...

Intra-Articular Injection Strategy Shows Efficacy Across Multiple Clinical Endpoints and Favorable Safety Profile After 12 Weeks of Therapy   Data From the Phase 2 Study Support the Potential of...

REDWOOD CITY, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics targeting the...

Forging a New Standard of Care in TGCT: Intra-Articular Administration of AMB-05X Tuesday, December 7th @ 1pm ET REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”),...

Intra-articular (IA) Delivery of AMB-05X Demonstrates Proof-of-Concept in TGCT With A Rapid Onset of Tumor Reduction in All Patients Within Six Weeks Interim AMB-05X Data Support Potential for...

REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing novel treatments with AMB-05X, its proprietary...

Novel Intra-articular Drug Delivery to Minimize Systemic Toxicity Associated with Currently Available TGCT Therapies First Set of Patient Data Expected in Second Half of 2021 REDWOOD CITY,...

REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its...